A modified tetracycline compound called DDOX demonstrates remarkable multi-target effects against Parkinson’s disease pathology. The non-antibiotic derivative prevents cellular uptake of toxic protein fibrils while addressing multiple aspects of disease progression.
The Hidden Architecture of Cancer’s Genetic Amplification Recent groundbreaking research published in Nature Cell Biology has uncovered a remarkable mechanism…
Breakthrough Research Illuminates NLRC4-Driven Autoimmune Condition In a landmark study published in Cellular & Molecular Immunology, researchers have developed a…
Groundbreaking Discovery in Malaria Research Scientists have achieved a major breakthrough in understanding one of malaria’s most important drug targets…
